

TERCICA INC
Form 8-K
May 03, 2005

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington D.C., 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date Of Report (Date Of Earliest Event Reported): 05/02/2005

Tercica, Inc.

(Exact Name of Registrant as Specified in its Charter)

Commission File Number: 000-50461

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

26-0042539
(I.R.S. Employer
Identification No.)

651 Gateway Boulevard
Suite 950
South San Francisco, CA 94080
(Address of Principal Executive Offices, Including Zip Code)

(650) 624-4900
(Registrant's Telephone Number, Including Area Code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
-

Edgar Filing: TERCICA INC - Form 8-K

Items to be Included in this Report

Item 8.01. Other Events

On May 2, 2005, Terica, Inc. (the "Company") issued a press release to announce that the Company has received Priority Review notification from the U.S. Food and Drug Administration for the New Drug Application for its drug candidate Increlex™ (mecasermin [rDNA origin] injection). The Company's press release is attached as Exhibit 99.1 to this report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

Press Release issued by Tercica, Inc. on May 2, 2005.

Signature(s)

Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.

Tercica, Inc.

Date: May 02, 2005.

By: /s/ Stephen N. Rosenfield

Stephen N. Rosenfield
Senior Vice President of Legal Affairs

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
EX-99.1	Press Release entitled "FDA Accepts Tercica's Increlex TM New Drug Application With Priority Review for the Treatment of Short Stature," dated May 2, 2005